A Phase 2 Study Evaluating the Efficacy and Safety of a Novel, Proprietary, Nano-Formulated, Lower Dose Oral Diclofenac

Pain Medicine (United States)

Volumn 13, Issue 11, 2012, Pages 1491-1498

  Manvelian, Garen ^a   Daniels, Stephen ^b   Gibofsky, Allan ^c  

^a Iroko Pharmaceuticals   (United States)

^b Premier Research   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Acute Pain; Anti Inflammatory; NSAIDs; Phase 2; Postoperative; SoluMatrix Technology

Indexed keywords

CELECOXIB; DICLOFENAC; PLACEBO;

ABDOMINAL PAIN; ADULT; ALVEOLAR OSTEITIS; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BLEEDING; CHILL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLUSHING; HEMATOMA; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MOLAR TOOTH; MOUTH INJURY; MULTICENTER STUDY; NAUSEA; NOSE OBSTRUCTION; OROPHARYNX PAIN; OSTEITIS; OTALGIA; PAIN; PALLOR; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWELLING; TOOTH DISEASE; TOOTH EXTRACTION; TOOTH PAIN; VOMITING;

EID: 84869168033     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01479.x     Document Type: Article

References (35)

1. Carr DB, Goudas LC. Acute pain. Lancet 1999;353:2051-8.
2. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Chronic Pain, 5th edition. Glenview, IL: APS; 2003.
3. Drug Topics. SDI/Verispan, VONA. 2009 top 200 generic drugs by total prescriptions. 2010. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252010/674982/article.pdf (accessed August 11, 2011).
4. Bakshi R, Frenkel G, Dietlein G, etal. A placebo-controlled comparative evaluation of diclofenac dispersible versus ibuprofen in postoperative pain after third molar surgery. J Clin Pharmacol 1994;34:225-30.
5. Bamber MJ, Tweedie IE, Breeze C, William NE. Premedication with controlled release diclofenac sodium reduces post-operative pain after minor gynaecological surgery. Eur J Anaesthesiol 1997;14:421-7.
6. Breivik EK, Barkvoll P, Skovlund E. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: A randomized, double-blind single-dose study. Clin Pharmacol Ther 1999;66:625-35.
7. Hersh EV, Levin LM, Adamson D, etal. Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. Clin Ther 2004;26:1215-27.
8. Matthews RW, Scully CM, Levers BG. The efficacy of diclofenac sodium (Voltarol) with and without paracetamol in the control of post-surgical dental pain. Br Dent J 1984;157:357-9.
9. Moore N. Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: A review of its pharmacology, clinical efficacy and safety. Clin Drug Investig 2007;27:163-95.
10. Chantler I, Mitchell D, Fuller A. The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic pain. Clin J Pain 2008;24:39-44.
11. Daniels SE, Baum DR, Clark F, etal. Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain. Curr Med Res Opin 2010;26:2375-84.
12. Kowalski M, Stoker DG, Bon C, Moore KA, Boesing SE. A pharmacokinetic analysis of diclofenac potassium soft-gelatin capsule in patients after bunionectomy. Am J Ther 2010;17:460-8.
13. Riff DS, Duckor S, Gottlieb I, etal. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: A Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Clin Ther 2009;31:2072-85.
14. Gluszko P, Bielinska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: Are we going to see the revival of cyclooxygenase-2 selective inhibitors? Pol Arch Med Wewn 2009;119:231-5.
15. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 2008;59(suppl 2):117-33.
16. Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: Achieving a balance. Arthritis Res Ther 2005;7(suppl 4):S14-22.
17. Lewis SC, Langman MJ, Laporte JR, etal. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6.
18. Riera-Guardia N, Castellsague J, Calingaert B, etal. The SOS Project: Nonsteroidal Anti-Inflammatory Drugs and Upper Gastrointenstinal Complications. Meta-Analysis of Epidemiological Studies. International Conference on Pharmacoepidemiology 2010. Brighton, United Kingdom; 2010.
19. Cambia. Package insert. Neurosciences N, ed. 2009.
20. Cataflam. Package Insert. East Hanover, NJ, Novartis Pharmaceuticals Corp. July 2005.
21. FlectorPatch. Prescribing Information. King Pharmaceuticals, Inc February 2011.
22. Pennsaid. Package Insert. Mallinckrodt Brand Pharmaceuticals, Inc 2009.
23. Voltaren. Prescribing Information. Novarttis Pharmaceuticals Corporation February 2011.
24. VoltarenGel. Prescribing Information. Novartis October 2009.
25. VoltarenXR. Package Insert. Novartis Pharmaceuticals Corporation 1988.
26. Zipsor. Package Insert. Xanodyne Pharmaceuticals, Inc 2009.
27. Cooper SA, Desjardins PJ. The value of the dental impaction pain model in drug development. Methods Mol Biol 2010;617:175-90.
28. Graham DJ, Campen D, Hui R, etal. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005;365:475-81.
29. Food and Drug Administration. Public health advisory-FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). 2005. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm (accessed September 15, 2011).
30. Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. 2004. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108361.htm (accessed September 15, 2011).
31. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 2009;10:808-19.
32. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007;369:1580-1.
33. Tomisato W, Tsutsumi S, Hoshino T, etal. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem Pharmacol 2004;67:575-85.
34. Chan AT, Manson JE, Albert CM, etal. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87.
35. Henry D, Lim LL, Garcia Rodriguez LA, etal. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ 1996;312:1563-6.